MBX Biosciences (MBX) shares were about 1.0% lower in Thursday trading following its Q2 results.
Earlier, the clinical-stage biopharmaceutical company reported a Q2 net loss of $0.78 per share, compared with a loss of $0.58 a year ago.
Looking ahead, the firm said its cash and investments are expected to support operations into 2029.
Price: 66.78, Change: -0.70, Percent Change: -1.04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.